St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
Developing decision-aligned statistical methods and computational tools to generate credible evidence for clinical trials in precision oncology, pediatric cancer and rare diseases.
The Pan Group develops statistical methods and computational tools to make clinical-trial evidence more timely, credible and useful for clinical-development decisions. Our work addresses challenges in precision oncology, pediatric cancers and rare diseases, where patient populations are often small, outcomes may mature slowly and evidence can be limited or heterogeneous.
Our research connects three complementary areas: efficient adaptive trial design and dose optimization; critical assessment and integration of external or counterfactual evidence; and dynamic monitoring that links the maturity of accumulating information to interim decisions. We develop open-source R packages and other practical tools to support transparent implementation and evaluation of these methods.
Close collaboration with St. Jude clinical investigators is central to our approach. Real trial questions motivate the methodology, and validated methods are translated back into study designs, protocols, statistical analysis plans, simulation studies and monitoring rules.
Our central goal is to connect clinical-development questions with statistical designs, credible evidence and appropriately supported decisions. We study Bayesian and adaptive methods for dose finding and optimization, single-arm and randomized trials, time-to-event endpoints, delayed treatment effects and multi-arm or platform designs. We also investigate the qualifications and assumptions required to use external information in clinical research.
Across these areas, we emphasize operating-characteristic calibration, estimand alignment, reproducibility and the transparent communication of uncertainty. Our methods are motivated by collaborative research in pediatric solid tumors and other rare conditions, with a focus on practical implementation in clinical trials.
Representative research and software are organized below by scientific objective. These three areas are connected by a common focus on generating evidence that is fit for a particular clinical decision.
We develop efficient trial designs for small and heterogeneous patient populations. Topics include Bayesian and model-assisted dose finding and optimization, seamless early-phase development, single-arm and randomized phase II studies, biomarker-enriched studies and multi-arm platform trials. Our work on the Keyboard design includes model-assisted dose finding for drug combinations.
Our objective is to align trial design and operating characteristics with the decisions investigators must make, including dose selection, futility, advancement of candidate treatments and the addition of new study arms.
PlatformDesign illustrates how preplanned experimental arms can be added during an ongoing multi-arm platform trial.
Historical controls and other external data can be valuable when a conventional concurrent control group is difficult to obtain, but similarity of observed outcomes alone is not enough to justify borrowing. Our research addresses how the target clinical question, populations, endpoints, time zero and data quality should be assessed before external evidence influences a trial.
This program builds on work in calibrated Bayesian borrowing and now includes publicly available research on Qualify-Then-Borrow (QTB). We are investigating external controls, causal transportability, counterfactual benchmarks, estimand alignment and sensitivity analyses; these remain methodological research areas rather than claims of a fully validated or deployed clinical prediction system.
The central question is not how much external information can be incorporated, but whether it is sufficiently qualified and relevant to support the particular inference or decision.
Evidence accumulates on different time scales in an ongoing trial. In pediatric oncology, endpoints such as progression-free and overall survival may require substantial follow-up, while decisions about futility, expansion or continued enrollment often cannot wait. We develop methods that make this tension explicit in prospective trial monitoring.
Our work includes Bayesian Go/No-Go rules, early futility monitoring, information-time alignment for time-to-event estimands, delayed treatment effects and non-proportional hazards, interim operating-characteristic calibration and adaptive decisions when realized enrollment differs from the original plan. These methods are designed to connect the maturity and credibility of the observed evidence with the decision being considered.
Example software - DTE-BOP2: Bayesian Optimal Phase II design under Delayed Treatment Effects
DTEBOP2 illustrates simulation-based trial planning when treatment effects may be delayed.
Our research is grounded in collaboration with clinicians and multidisciplinary trial teams. Statistical methods are translated into study designs, protocols, operating-characteristic simulations, interim monitoring procedures, statistical analysis plans and reproducible software. The aim is to provide both an appropriate method and a transparent basis for the clinical-development decision it supports.
A related direction is Evidence-to-Decision (E2D), which organizes statistical evidence around specific future development actions rather than a single generic declaration that a treatment is promising. We are also exploring carefully validated, AI-assisted workflows for organizing and reproducing evidence-generation tasks; scientific validity and consequential decisions remain subject to statistical evaluation, clinical judgment and human oversight.
Haitao Pan, PhD
Associate Member, St. Jude Faculty
Department of Biostatistics
MS 768, Room R6030
St. Jude Children's Research Hospital